<DOC>
	<DOCNO>NCT01404741</DOCNO>
	<brief_summary>5-azacytidine treatment prolongs survival patient myelodysplastic syndrome ( MDS ) , cure disease . Allogeneic stem cell transplantation curative treatment option associate high risk treatment-related morbidity mortality . In current trial allogeneic stem cell transplantation compare 5-azacytidine treatment accord donor availability elderly patient MDS ( 55-70 year ) .</brief_summary>
	<brief_title>5-azacytidine Treatment Versus 5-azacytidine Followed Allogeneic Stem Cell Transplantation Elderly Patients With Myelodysplastic Syndrome ( MDS )</brief_title>
	<detailed_description>5-azacytidine treatment prolongs survival patient myelodysplastic syndrome ( MDS ) , cure disease . Allogeneic stem cell transplantation curative treatment option associate high risk treatment-related morbidity mortality . Dose-reduced conditioning prior transplantation allow also treatment elderly patient MDS . In current trial allogeneic stem cell transplantation compare 5-azacytidine treatment accord donor availability elderly patient MDS ( 55-70 year ) .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Patients proven de novo therapyrelated MDS / CMML ( WBC &lt; 13 GPT/l ) accord FAB risk profile accord IPSS : intermediate II risk highrisk intermediate I highrisk cytogenetic ( accord IPSS , take account IPSS , however , validate MDS ) , patient secondary AML ( accord WHO ) blast ≤ 30 % ( = RAEBt accord FAB ) Previously untreated maximal 1 cycle 5azacytidine ( Vidaza® ) Male Female ; Age 55 70 year Understand voluntarily sign informed consent form ECOG performance status ≤ 2 study entry Adequate renal liver function : creatinine bilirubin &lt; 3 x upper limit normal Sufficient cardiac function ( ejection fraction &gt; 30 % ) Blasts &gt; 30 % bone marrow time diagnosis Central nervous involvement Severe irreversible renal , hepatic , pulmonary cardiac disease , Total bilirubin , SGPT SGOT ≥ 3 time upper normal level Left ventricular ejection fraction &lt; 30 % Creatinine clearance &lt; 30 ml/min DLCO &lt; 35 % and/or receive supplementary continuous oxygen Pregnant breastfeed female subject Patients lifeexpectancy less six month another debilitate disease Serious psychiatric psychological disorder Uncontrolled invasive fungal infection time registration Known positive HIV acute infectious hepatitis , type A , B C Participation another study ongoing use unlicensed investigational product 28 day study enrollment end study</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>MDS</keyword>
	<keyword>CMML</keyword>
	<keyword>allogeneic stem cell transplantation</keyword>
	<keyword>5-azacytidine</keyword>
</DOC>